Arbutus Biopharma Corporation (ABUS) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Arbutus Biopharma Corporation (NASDAQ: ABUS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $4.00 (-4.99% 1D, market cap $645.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABUS ranks #997 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABUS carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMMX (Immix Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and LXRX (Lexicon Pharmaceuticals Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -31.5%, cap $631.8M). Among the 5-stock peer group, ABUS leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per ABUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001447028), Arbutus Biopharma Corporation generated $14.1M in revenue (+128.2% YoY), -$33.5M in net income, and -$39.6M in free cash flow against $94.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±7% realized swing band)
Altman Z-Score 1.34 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ABUS currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.67) and Max Pain ($4.20) forces dealer call-delta covering toward $5.72.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Arbutus Biopharma Corporation (ABUS) dropped -4.99% to $4.00, trading at 26% of its 52-week range ($3.5 – $5.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Seeking Alpha report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
MyChesCo report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that
The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +128.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ABUS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ABUS. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Arbutus Biopharma Corporation (ABUS) ranks #997 by composite RQD confidence (18/100, grade E) and #403 by equity capitalization ($645.3M). Within this direct 5-issuer industry benchmark cohort, ABUS leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with ABUS at 18/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABUS
ACTIVE
Arbutus Biopharma Corporation | E | 18/100 | — | — | -35.0% | -4.99% | $645.3M | Benchmark Subject |
| IMMX Immix Biopharma Inc. | E | 29/100 | — | — | -35.0% | -5.47% | $636.7M | /immx-vs-abus → |
| LXRX Lexicon Pharmaceuticals Inc. | E | 26/100 | — | 96.0% | -31.5% | +1.41% | $631.8M | /lxrx-vs-abus → |
| DSGN Design Therapeutics Inc. | E | 33/100 | — | — | -32.1% | -4.96% | $668.4M | /dsgn-vs-abus → |
| ANL Adlai Nortye Group Ltd. | D | 46/100 | — | — | — | -1.88% | $615.0M | /anl-vs-abus → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arbutus Biopharma Corporation (ABUS) reported GAAP revenue of $14.1M (+128.2% vs. FY2024 revenue of $6.2M , and -22.4% cumulative change since FY2023) , GAAP net income of -$33.5M, operating cash flow of -$39.6M, and free cash flow of -$39.6M (+39.1% YoY). On the balance sheet, ABUS closed FY2025 with $94.6M in total assets against $0 in total debt (Altman Z-Score: 1.34, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $14.1M | -$33.5M | -$39.6M | -$39.6M | $94.6M | — |
| FY2024 (FY) | 2024-12-31 | $6.2M | -$69.9M | -$64.8M | -$65.0M | $131.7M | — |
| FY2023 (FY) | 2023-12-31 | $18.1M | -$72.8M | -$85.9M | -$85.9M | — | — |
As of 2026-11-03, Arbutus Biopharma Corporation (NASDAQ: ABUS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $4.00 (-4.99% 1D, market cap $645.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABUS ranks #997 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABUS carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMMX (Immix Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and LXRX (Lexicon Pharmaceuticals Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -31.5%, cap $631.8M). Among the 5-stock peer group, ABUS leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per ABUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001447028), Arbutus Biopharma Corporation generated $14.1M in revenue (+128.2% YoY), -$33.5M in net income, and -$39.6M in free cash flow against $94.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ABUS last traded at $4.00 (-4.99% on volume of 2,651,058 shares), positioning the stock -14.35% below its 50-day simple moving average ($4.67) and -10.91% below its 200-day simple moving average ($4.49). Across its 52-week range of $3.50 to $5.45, ABUS sits at the 25.6% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±7.0% ($3.72 to $4.28).
Arbutus Biopharma Corporation (ABUS) earns a live Roarable RQD composite score of 18/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.00 (-4.99% 1D, market capitalization $645.3M).
Arbutus Biopharma Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Reported revenue was $14.1M for FY 2025, . Market capitalization is $0.7B.0M in market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Arbutus Biopharma Corporation (ABUS) reported $14.1M in annual revenue (up from $6.2M in FY2024, +128.2% YoY) and -$33.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($18.1M revenue, -$72.8M net income) through FY2025, ABUS scaled operating cash flow to -$39.6M and free cash flow to -$39.6M, backed by $94.6M in total assets against $0 in total debt.
Second-order bottlenecks cannot be identified from the provided sources.
Real-time company headlines, analyst actions, and sector developments for Arbutus Biopharma Corporation (ABUS) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
MyChesCo report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on ABUS here at $4.21: The FDA lifted the AB-101 clinical hold and the company is retiring 23% of shares in a $230 Million buyback, as reported in the news feed.. Compare ABUS's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $4.00 are getting bought.
@BearTrap_Alert Shorting a 5/20 institutional whale-flow stock at $4.21 is dangerous when funds are rotating into Health Care.
I respect the product at Arbutus Biopharma Corporation, but the stock at $4.21 is a different story. The RQD Score of 18 (E) is driven by ROIC of -35%, Altman Z of 1.34, and cash falling from $36.3M to $18.0M against FCF of -$39.6M.. FCF yield is -6.04% and RQD sits at 18/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).